Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline

Jul 07 2017

• By Joseph Haas

Business decline

Related Content

Endo Continues To Expand Generics Business With Par Acquisition

May 18 2015

Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request

Jul 06 2017

Related Companies

Endo, Inc.

Par Pharmaceutical Companies Inc.

Grupo Farmaceutico Somar

Amneal Pharmaceuticals, Inc.

Collegium Pharmaceutical, Inc.

Additional Topics

Drug Safety Business Strategies Risk Management FDA Commercial Neurology BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window